LVEF

GE HealthCare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

Retrieved on: 
Wednesday, April 3, 2024
Technology, Mobile, Wireless, Health, Apps, Applications, Radiology, Professional Services, Artificial Intelligence, Medical Devices, Software, Hospitals, Data Analytics, Health Technology, Data Management, Cardiology, Diagnosis, Cardiovascular disease, Prevalence, CVD, Intelligence, Patient, Acquisition, Death, Master of Science, LVEF, Caption, American College, GE HealthCare, Heart, Atrial fibrillation, ACC, Medical imaging

GE HealthCare (Nasdaq: GEHC) today announced the launch of Caption AI artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care on Vscan Air SL.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) today announced the launch of Caption AI artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care on Vscan Air SL.
  • Now, with Caption AI technology, clinicians using Vscan Air SL handheld ultrasound will have access to real-time, step-by-step guidance to capture diagnostic-quality images and automated ejection fraction estimation to help inform clinical decisions across cardiac settings.
  • Vscan Air SL with Caption AI is designed to lower the threshold for healthcare professionals to be able to capture cardiac images so that even non-expert ultrasound users can take a quick look at patients’ hearts.
  • "The integration of Caption AI with the Vscan Air SL handheld ultrasound opens an entirely new chapter for cardiac screening.

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

Retrieved on: 
Monday, March 25, 2024
Health, Clinical Trials, General Health, Pharmaceutical, Cardiology, Biotechnology, BMY, Patient, Mitigation, Bristol Myers Squibb, MD, Senior, LVEF, American College, Safety, REMS, ACC, Risk, Hospital, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6-8, 2024 in Atlanta, Georgia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6-8, 2024 in Atlanta, Georgia.
  • These data are consistent with the clinical development program and reinforce the safety profile of CAMZYOS in clinical practice.
  • This effectiveness and safety information about ELIQUIS use in clinical practice can supplement data from randomized clinical trials.
  • Visit this page on BMS.com for more information on Bristol Myers Squibb’s scientific approach and resources on cardiovascular diseases.

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Retrieved on: 
Wednesday, March 6, 2024
MRI, Therapy, SAN, Biotechnology, Skeleton, FDA, DMD, Duchenne muscular dystrophy, Conference, Patient, OLE, Cardiac muscle, Exosome, MDA, LVEF, Episcopal conference, PUL, Pharmaceutical industry

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year’s MDA Clinical and Scientific Conference which is taking place in Orlando, Florida from March 3-6, 2024.

Key Points: 
  • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year’s MDA Clinical and Scientific Conference which is taking place in Orlando, Florida from March 3-6, 2024.
  • CAP-1002 revealed clinically meaningful improvements in ameliorating cardiac function.
  • “We are pleased to be presenting our positive long-term open label extension data at this year’s MDA Conference,” said Linda Marbán, Ph.D., chief executive officer of Capricor.
  • These two-year results suggest that CAP-1002 has the potential to slow the decline of DMD progression and speaks to the potential long-term benefit for patients.

Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.

Retrieved on: 
Tuesday, February 20, 2024
Data Management, Health, Technology, Health Technology, Software, General Health, Cardiology, Real-World Evidence, Woman, Cardiovascular disease, EHR, CVD, MDRX, Data, Heart failure, Prevalence, Natural language processing, Hypertension, BMI, Death, Patient, Natural language, Body mass index, LVEF, Coronary artery disease, NLP, Dietary supplement

Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.

Key Points: 
  • Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.
  • Using structured and unstructured data from the comprehensive Veradigm Network EHR dataset, the report presents cardiovascular condition prevalence by state and three-digit zip code.
  • Veradigm also examines the prevalence of cardiovascular conditions such as dyslipidemia/hyperlipidemia and hypertension in relation to body mass index (BMI) categories.
  • Veradigm has a variety of additional data sources including clinically enriched Veradigm Network EHR Data across various therapeutic areas and the Veradigm Cardiovascular and Metabolic Registries.

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Retrieved on: 
Monday, February 19, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NSCLC, Fever, Progression-free survival, PFS, AstraZeneca, Heart, Periodic breathing, QT interval, MD, Chemoradiotherapy, Cough, Pemetrexed, Winship Cancer Institute, QT, OS, Electrolyte, Cardiomyopathy, Lung cancer, Safety, Emory University, CRT, LAURA, ILD, Patient, LVEF, Brain, Pharmaceutical industry

In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.

Key Points: 
  • In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.
  • Interstitial lung disease (ILD)/pneumonitis occurred in 4% of the 1813 TAGRISSO-treated patients; 0.4% of cases were fatal.
  • TAGRISSO is the only targeted therapy to improve patient outcomes in both early-stage disease in the ADAURA Phase III trial and late-stage disease in the FLAURA Phase III trial and FLAURA2 Phase III trial .
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

Retrieved on: 
Saturday, February 17, 2024
Oncology, FDA, Health, General Health, Pharmaceutical, Biotechnology, Heart, QT interval, Food, Pemetrexed, Risk, Cardiomyopathy, Electrolyte, Death, Patient, LVEF, Priority review, Pharmaceutical industry

This approval reinforces TAGRISSO as the backbone of EGFR-mutated lung cancer treatment either as monotherapy or in combination with chemotherapy.

Key Points: 
  • This approval reinforces TAGRISSO as the backbone of EGFR-mutated lung cancer treatment either as monotherapy or in combination with chemotherapy.
  • The safety profile of TAGRISSO with the addition of chemotherapy was generally manageable and consistent with the established profiles of the individual medicines.
  • Adverse event (AE) rates were higher in the TAGRISSO plus chemotherapy arm, driven by well-characterized chemotherapy-related AEs.
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten

Retrieved on: 
Thursday, January 25, 2024
Tricuspid valve, Patient, Architecture, Fibrosis, Heart, Hemodynamics, CMR, SAN, Sudden death, Pulmonary fibrosis, LVEF, Research and development, Hypertrophic cardiomyopathy, Disease, Cytokinetics, LVOT, Research, Week, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM).
  • At the time of this analysis, 16 patients in FOREST-HCM had completed a CMR at baseline and at Week 48.
  • Baseline characteristics of the CMR cohort were comparable to the overall patient population in FOREST-HCM.
  • We look forward to expanding on these data in the future.”

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
Trigger, Annual general meeting, Chemistry, Patient, Small RNA, Exosome, PLOS, Kidney, Webcast, Therapy, Exon, Business, MUSCULAR, Employment, Food, International, PUL, LVEF, RRM2, Ovarian cancer, Duchenne muscular dystrophy, MRI, Horizon, Commercialization, Amgen, WMS, ID, AAEV, BLA, Cohort, Vaccine, Tissue, Distribution deal, PPMD, Asos, Partnership, Biologics license application, DMD, Apoptosis, Distribution, Liver, Protein, Biotechnology, Cohort study, Mouse, Poster, Omicron, FDA, Seminal vesicles, File, CMC, HIV disease progression rates, Dietary supplement, Mobile phone, Pharmaceutical industry, Fine chemical, Video game, Nursing

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Next steps for Cohort A:
    Plan to report the outcome from the interim futility analysis in the fourth quarter of 2023.
  • Held a positive Type-B clinical meeting with FDA in the third quarter of 2023.
  • Next steps for Cohort B:
    Expect to commence enrollment for Cohort B in the fourth quarter of 2023.
  • Revenues for the third quarter of 2023 were approximately $6.2 million compared with approximately $1.6 million for the third quarter of 2022.

Cytokinetics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Randomness, FDA, National Medical Products Administration, Standard of care, Research, Heart failure, Manuscript, American College, NMPA, Food, Center for Drug Evaluation and Research, Pivotal, LVEF, OND, Symantec Endpoint Protection, Safety, Cytokinetics, Organization, MAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal of Cardiac Failure, Obstruction, SAD, Journal, Cardiology, CRL, Disopyramide, ALS, Clinical trial, CDE, EMA, Șaeș, Assessment, NDA, Investment, LVOT, Plasma protein binding, Pharmaceutical industry, Medical device, Patient, Pharmacokinetics, Pharmacology, HCM, EU

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2023. Net loss for the third quarter was $129.4 million, or $1.35 per share, compared to net loss for the third quarter of 2022 of $142.3 million, or $1.52 per share. Cash, cash equivalents and investments totaled $554.7 million on September 30, 2023.

Key Points: 
  • On Track for Topline Results from SEQUOIA-HCM,
    a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM,
    the Open-Label Extension Study of Aficamten,
    SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2023.
  • Net loss for the third quarter was $129.4 million, or $1.35 per share, compared to net loss for the third quarter of 2022 of $142.3 million, or $1.52 per share.
  • “During the third quarter we made considerable progress across our specialty cardiology franchise, with aficamten remaining our top priority.
  • During the quarter we also started ACACIA-HCM, a pivotal Phase 3 clinical trial of aficamten in patients with non-obstructive HCM.

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Retrieved on: 
Wednesday, November 1, 2023
Female, MTD, BMI, Therapy, ASTS, Life, LVEF, Doxorubicin, Kidney, Quality of life, Male, SD, Life expectancy, Index, Hypertension, Risk, Annual general meeting, RECIST, Cancer, Patient, Toxicity, Diagnosis, Heart failure, Toxic leukoencephalopathy, Pharmaceutical industry

The Phase 1b clinical trial has enrolled 14 ASTS patients (9 female and 5 male) to-date ranging in age from 26 to 81 years (median = 52.5 years) across five dose cohorts.

Key Points: 
  • The Phase 1b clinical trial has enrolled 14 ASTS patients (9 female and 5 male) to-date ranging in age from 26 to 81 years (median = 52.5 years) across five dose cohorts.
  • The trial is currently ongoing and is in the fifth dose level cohort (650 mg/m2).
  • So far, 9 out of the 14 patients have had stable disease (SD, as defined by RECIST 1.1 criteria) after camsirubicin treatment.
  • Camsirubicin was designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin.